Table 1.
Patient Characteristics
| Characteristic | N (%) /Median (range) |
|---|---|
| Patient number | 36 |
| Gender (male/female) | 31/5 |
| Patient age at HCT, years, median (range) | 56 (35–72) |
| Diagnosis, No. | |
| Acute myeloid leukemia | 13 |
| Myelodysplastic syndrome | 6 |
| Chronic lymphocytic leukemia | 7 |
| Non Hodgkin lymphoma | 4 |
| Chronic myeloid leukemia | 2 |
| Myeloproliferative disorder | 2 |
| Multiple myeloma | 1 |
| Non Hodgkin lymphoma and myelodysplastic syndrome | 1 |
| Disease status at time of study intervention | |
| CR | 13 |
| Not in CR* | 23 |
| Donor source | |
| HLA-matched related | 17 |
| HLA-matched unrelated | 18 |
| 1-allele HLA-mismatched unrelated | 1 |
| Transplant conditioning intensity | |
| Nonmyeloablative (fludarabine/TBI) | 34 |
| Myeloablative | |
| Busulfan/Cyclophosphamide | 1 |
| Fludarabine/TBI/anti-CD45 Ab | 1 |
| GVHD prophylaxis after transplant | |
| MMF/cyclosporine | 25 |
| MMF/cyclosporine/sirolimus | 2 |
| MMF/tacrolimus | 6 |
| MF/tacrolimus/sirolimus | 2 |
| Cyclosporine/methotrexate | 1 |
| Acute GVHD before DLI | |
| None | 30 |
| Grade II-III | 6 |
| Time from HCT to DLI | |
| ≤100 days | 21 |
| >100 days | 15 |
| % of donor CD3 chimerism at time of DLI, median (range) | 28 (5–47) |
*
Evidence of disease: residual lymphadenopathy (n=8), bone marrow morphology (CLL (n=2); myelofybrosis (n=6)), minimal residual disease detected by marrow flow cytometry/cytogenetics/FISH (n=7).